Affectis Pharmaceuticals is developing new treatments for depression and schizophrenia. Based on clinical and preclinical data, our programs offer an innovative approach to these very large markets. The company has two main programs:

• AF-4025, a P2X7 agonist, which is scheduled to complete preclinical testing in Q1, 2008 with phase I studies to start shortly thereafter.
• Cimicoxib, currently in a phase II depression trial. A phase II trial in schizophrenia and another in treatment resistant depression will start early 2008.
Our third program is an antagonist against P2X7 at the lead optimization stage.

Speaker Profile

Herbert Stadler

Over the last two decades, Herbert Stadler has built a track record as one of Germany's most active biotech entrepreneurs. He has founded or co-founded several biotech companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH and DeveloGen AG. Herbert Stadler is a neurochemist by training.
 
He obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification ("Habilitation") at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen. He currently serves on the supervisory boards of DeveloGen AG and IBA GmbH.